Richard Eiswirth - Alimera Sciences Pres and CFO

ALIMDelisted Stock  USD 5.54  0.01  0.18%   

CFO

Mr. Richard S. Eiswirth, Jr., will be appointing as a President, Chief Executive Officer of the Company., effective January 2, 2019. He has served as President and Chief Financial Officer of our Company since January 2016. Mr. Eiswirth previously served as our Chief Operating Officer and Chief Financial Officer from August 2010 until December 2015 and as our Chief Financial Officer from October 2005 to August 2010. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, engaged in consumer products acquisition activities. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc., a financial consultancy he founded in 2002. Mr. Eiswirth served as Chief Financial Officer and Senior Executive Vice President of Netzee, Inc., a provider of Internet banking solutions to community banks from 1999 to 2002. Mr. Eiswirth held various positions with Arthur Andersen, where he began his career, from 1991 to 1999. Mr. Eiswirth serves as a director of Celtaxsys Inc., a privately held biotechnology company, where he also chairs the audit committee. Mr. Eiswirth previously served as chairman, audit committee chairman and member of the compensation committee of Jones Soda Co., a Seattle, Washington based beverage company, and as director and audit committee chairman of Color Imaging, Inc., a Norcross, Georgia based manufacturer of printer and copier supplies. Mr. Eiswirth was previously a Certified Public Accountant in Georgia since 2019.
Age 56
Tenure 5 years
Phone678 990 5740
Webhttps://alimerasciences.com
Eiswirth holds a B.A. in accounting from Wake Forest University.

Richard Eiswirth Latest Insider Activity

Tracking and analyzing the buying and selling activities of Richard Eiswirth against Alimera Sciences stock is an integral part of due diligence when investing in Alimera Sciences. Richard Eiswirth insider activity provides valuable insight into whether Alimera Sciences is net buyers or sellers over its current business cycle. Note, Alimera Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Alimera Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Alimera Sciences Management Efficiency

Alimera Sciences' management efficiency ratios could be used to measure how well Alimera Sciences manages its routine affairs as well as how well it operates its assets and liabilities.
Alimera Sciences currently holds 67.4 M in liabilities. Alimera Sciences has a current ratio of 1.27, suggesting that it is in a questionable position to pay out its financial obligations when due. Note, when we think about Alimera Sciences' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 3 records

CFO Age

Joshua FineCyclo Therapeutics
42
Ryan CPALifecore Biomedical
47
John MorbergLifecore Biomedical
60
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia. Alimera Sciences operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 145 people. Alimera Sciences (ALIM) is traded on NASDAQ Exchange in USA and employs 154 people.

Management Performance

Alimera Sciences Leadership Team

Elected by the shareholders, the Alimera Sciences' board of directors comprises two types of representatives: Alimera Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alimera. The board's role is to monitor Alimera Sciences' management team and ensure that shareholders' interests are well served. Alimera Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alimera Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Christopher Visick, General VP
Philip Ashman, Sr. VP and European Managing Director
Jason Werner, Chief Officer
David Holland, Co-Founder and Sr. VP of Sales and Marketing
Todd Wood, President Operations
Richard Eiswirth, Pres and CFO
Charles Myers, NonEx Consultant
David MD, Chief Specialist
Elliot CPA, CFO Treasurer

Alimera Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alimera Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in Alimera Stock

If you are still planning to invest in Alimera Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alimera Sciences' history and understand the potential risks before investing.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum